gdc
FDA Approvals, News & UpdatesMelanomaNewsworthy

Braftovi plus Mektovi a New Combination for Metastatic Melanoma with BRAF Mutation

October 2018 Vol 4 No 5 – October 17, 2018

In June 2018, the FDA approved 2 new drugs Braftovi and Mektovi (encorafenib and binimetinib; from Array BioPharma) to be used in combination for the treatment of patients with unresectable (can’t be removed by surgery) or metastatic (spreading) melanoma and a BRAF V600E or V600K mutation. At the same time, the FDA also approved the THxID-BRAF kit, which is a test to identify a BRAF mutation. Patients should have this new genetic test to identify the BRAF mutation before using this new targeted drugs combination.

The FDA approved this new combination based on a clinical trial of 577 patients with unresectable or metastatic melanoma and BRAF V600E or BRAF V600K mutation. The results showed that the average time without disease progression was 14.9 months with the new combination compared with only 7.3 months with another drug, Zelboraf (vemurafenib), which was previously approved for patients with melanoma.

The most common side effects with the new combination were fatigue, nausea, diarrhea, vomiting, abdominal pain, and joint inflammation. A few patients (5%) discontinued treatment with the new drugs because of bleeding and headache.

Recommended For You
FDA Approvals, News & UpdatesLeukemia
Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation
In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
Breast CancerFDA Approvals, News & Updates
Piqray New Treatment Approved for Metastatic Breast Cancer and PI3KCA Mutation
In May 2019, the FDA approved Piqray (alpelisib), the first PI3K inhibitor for the treatment of metastatic breast cancer with a PI3KCA mutation in postmenopausal women, and in men. An FDA spokesperson said it was the first treatment “to demonstrate a clinically meaningful benefit” for this type of breast cancer.
Bladder CancerFDA Approvals, News & Updates
Balversa First Targeted Drug Approved for Metastatic Bladder Cancer with FGFR Genetic Alterations
In April 2019, the FDA approved Balversa, an FGFR kinase inhibitor, for the treatment of adults with advanced or metastatic bladder cancer and an FGFR genetic alteration, as determined by an FDA-approved diagnostic test. This is the first FDA-approved targeted drug for patients with this specific genetic mutation.
Last modified: October 27, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country